Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.

@article{GarciaRivera2012MultipleMI,
  title={Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.},
  author={Jose A. Garcia-Rivera and Michael D. Bobardt and Udayan Chatterji and Sam Hopkins and Matthew A Gregory and Barrie Wilkinson and Kai Lin and Philippe A Gallay},
  journal={Antimicrobial agents and chemotherapy},
  year={2012},
  volume={56 10},
  pages={5113-21}
}
Alisporivir is the most advanced host-targeting antiviral cyclophilin (Cyp) inhibitor in phase III studies and has demonstrated a great deal of promise in decreasing hepatitis C virus (HCV) viremia in infected patients. In an attempt to further elucidate the mechanism of action of alisporivir, HCV replicons resistant to the drug were selected. Interestingly, mutations constantly arose in domain II of NS5A. To demonstrate that these mutations are responsible for drug resistance, they were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…